The activities of tissue xanthine oxidase and adenosine deaminase and the levels of hydroxyproline and nitric oxide in rat hearts subjected to doxorubicin: protective effect of erdosteine

被引:42
作者
Fadillioglu, E [1 ]
Yilmaz, HR
Erdogan, H
Sogut, S
机构
[1] Inonu Univ, Fac Med, Dept Physiol, TR-44069 Malatya, Turkey
[2] Suleyman Demirel Univ, Fac Med, Dept Med Biol & Genet, Isparta, Turkey
[3] Mustafa Kemal Univ, Fac Med, Dept Biochem, Antakya, Turkey
关键词
doxorubicin; erdosteine; xanthine oxidase; adenosine deaminase; nitric oxide; hydroxyproline;
D O I
10.1016/S0300-483X(03)00258-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this experimental study was to investigate the effects of erdosteine, an antioxidant agent, on doxorubicin (DXR)-induced cardio-toxicity through nitric oxide (NO) levels, collagen synthesis, xanthine oxidase (XO) and adenosine deaminase (ADA) activities in rats. Rats were treated with erdosteine (10 mg/kg b.wt. per day, orally) or saline starting 2 days before administrating a single dose of DXR (20 mg/kg i.p.) or saline. At the 10th day of the DXR administration, hearts were removed under anesthesia for biochemical measurements. Enzyme activities as well as OH-proline and NO levels were found to be significantly increased in DXR group compared with the control group. All of the parameters studied except ADA activity were decreased significantly approximating to the control levels upon erdosteine administration. In conclusion, erdosteine seems to be an alternative agent for protection of cardiac tissue against DXR-induced cardio-toxicity through its regulatory effect on XO activity and NO level. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 33 条
[1]   Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance [J].
Adams, V ;
Jiang, H ;
Yu, JT ;
Möbius-Winkler, S ;
Fiehn, E ;
Linke, A ;
Weigl, C ;
Schuler, G ;
Hambrecht, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 33 (04) :959-965
[2]  
Braga PC, 2000, ARZNEIMITTELFORSCH, V50, P739
[3]   DIFFERENCES IN THE REGIONAL DISTRIBUTION AND RESPONSE TO ISCHEMIA OF ADENOSINE-REGULATING ENZYMES IN THE HEART [J].
CHOONG, YS ;
HUMPHREY, SM .
BASIC RESEARCH IN CARDIOLOGY, 1987, 82 (06) :576-584
[4]  
CORTAS NK, 1990, CLIN CHEM, V36, P1440
[5]   THE MOLECULAR PHARMACOLOGY OF DOXORUBICIN INVIVO [J].
CUMMINGS, J ;
ANDERSON, L ;
WILLMOTT, N ;
SMYTH, JF .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (05) :532-535
[6]  
DALLEDONNE I, 1993, CANCER BIOCHEM BIOPH, V13, P245
[7]   Erdosteine [J].
Dechant, KL ;
Noble, S .
DRUGS, 1996, 52 (06) :875-881
[8]  
DOROSHOW JH, 1983, CANCER RES, V43, P460
[9]   Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats [J].
Fadillioglu, E ;
Erdogan, H ;
Sögüt, S ;
Kuku, I .
JOURNAL OF APPLIED TOXICOLOGY, 2003, 23 (01) :71-74
[10]   Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats [J].
Fadillioglu, E ;
Erdogan, H .
PHARMACOLOGICAL RESEARCH, 2003, 47 (04) :317-322